Castilla y León‘s Bold Leap: Charting the Future of Precision Medicine
Castilla y León in Spain has made a significant move, launching its ambitious Strategic Plan for Precision Personalized Medicine (PEMPPCyL) for 2024-2030. This isn’t just a plan; it’s a roadmap for a healthcare revolution. The goal? To deliver more customized, effective, and sustainable healthcare, leveraging cutting-edge tech like omics and artificial intelligence. The vision is clear: ensuring every citizen in the region benefits from personalized medicine, bringing Castilla y León in line with the best practices in Europe.
Deciphering the PEMPPCyL: A Blueprint for Tomorrow
The PEMPPCyL is designed as an overarching strategy, a “umbrella plan” to drive this innovative approach to healthcare. The plan is structured around six strategic pillars: governance, healthcare resources, digital health, quality and ethics, training, and research & innovation. The initiative aims to foster a collaborative, networked healthcare system, where hospitals, primary care, labs, and other stakeholders unite to offer personalized treatments and more precise diagnoses.
The plan focuses on “Reference Assistance Nodes (RANs)” equipped with high-performance tech and “Reference Multidisciplinary Teams (RMTs)” that bring care closer to patients across all health areas. The core strategy integrates advanced tech, such as massive sequencers and AI systems, with a humanistic and ethical approach, protecting privacy and promoting fairness.
Priorities include integrating genomics, advanced therapies, and digital health, as well as continuous training for healthcare professionals, with a focus on clinical genetics and bioinformatics. The plan also aims to bolster biomedical research and encourage active patient involvement.
Coordination: The Cornerstone of Advanced Medicine
María Isidoro, the regional coordinator of the PEMPPCyL, emphasizes that coordination is paramount. She points to the Integral Plan for Rare Diseases of Castilla y León (PIERCyL) as a prime example of the model, which has received national recognition. The success of the rare disease units in establishing coordination served as a template for the wider plan. This approach extends to all specialized areas, supported by RANs equipped with cutting-edge labs and RMTs providing accessible clinical support across all health areas.
The RANs, or Reference Assistance Nodes, are crucial, housing high-performance equipment essential for implementing personalized medicine based on individual patient characteristics. These nodes guarantee equitable access to care, regardless of where a person lives in Castilla y León. In pediatrics, the DiERCyL unit in Salamanca is the sole reference, while for adults, there are four main nodes in Salamanca, Valladolid, Burgos, and León.
Castilla y León has pioneered significant advancements, including the first mass sequencer for complete genome studies in its service portfolio for over two years. This advancement enables patients to access genetic studies via hospital care. Artificial intelligence is also playing a pivotal role in increasing diagnostic rates.
The plan covers specialties showing notable progress, such as precision oncology, allergology, cardiology, and precision psychiatry, where Castilla y León is at the forefront. For instance, in allergology, the region is at the international forefront in the application of omics like epigenomics and transcriptomics and uses neural networks to predict antibiotic allergies.
“Governance is the most solid axis,” explains Isidoro, “because the plan’s design itself sets the framework that guides its implementation. This sets us apart from other communities that do not have such a defined framework.” The plan includes training for healthcare professionals and patients and collaboration with associations like FEDER to incorporate patient perspectives.
Ethically, Isidoro stresses that while legal frameworks exist, technology is evolving faster. Rigorous standards will be applied to safeguard data protection, fairness, and dignity. Funding comes from Europe, the Ministry of Health, and the Regional Ministry of Health, with specific allocations for technology, training, and coordination.
PIERCyL: Advanced Therapies and a Model of Excellence
The Integral Plan for Rare Diseases of Castilla y León (PIERCyL), part of the PEMPPCyL, is a standout national initiative. Dr. Fermín Sánchez-Guijo, a professor and head of the Hematology Department at the University Hospital of Salamanca and an expert in advanced therapies, highlights the CAR-T therapy as a prime example of personalized precision medicine. This therapy involves genetically modifying a patient’s lymphocytes to eliminate specific malignant cells. Castilla y León pioneered this therapy in Spain in 2019.
The PIERCyL has established a network of certified healthcare centers for administering these therapies, managed by a centralized expert committee that assesses each case. It has also promoted public research and the in-house manufacturing of advanced therapy medicines.
The University Hospital of Salamanca is a leader in this area, with a Cell Production Unit accredited since 2009 and new facilities being validated to manufacture CAR-T cells and other advanced medicines. This unit integrates a laboratory, apheresis sections, cryobiology, and a highly experienced multidisciplinary clinical team.
Fermín notes that the monitoring of the effectiveness and safety of these therapies is conducted through rigorous protocols, reported to national systems like VALTERMED and international registries. Training is another crucial aspect, with the NOVARTIS-USAL100 Advanced Therapies Chair training resident doctors and students in this field.
In clinical and translational research, the Regional Strategy for Advanced Therapies aims to establish Castilla y León as a national and international leader in advanced cell therapies. Patient selection for these therapies is based on genetic tests, integrated into the Diagnostic and Personalized Medicine Unit in Hemato-Oncology.
The model ensures equitable access to these highly specialized treatments through a networked coordination with all hospitals in the community, along with streamlined communication protocols with Primary Care. Data privacy and protection are strictly maintained. Fermín concludes that the PIERCyL has received national recognition for its innovative methodology, which guides and personalizes therapies to improve the health of patients in Castilla y León.
PIERCyL and DIERCyL: Key Interviews on Rare Disease Care
To delve deeper into Castilla y León’s plans for rare diseases, Dr. Pablo Prieto, clinical coordinator of the DiERCyL Pediatric Rare Diseases Reference Unit, and Dr. María Luisa Pérez, clinical coordinator of the Adult Reference Assistance Node at the Hospital de Salamanca, provide specialized insights, with support from Dr. María Isidoro, the regional coordinator of the PEMPPCyL.
Structure and Coordination
María Isidoro explains that the plan is network-based, coordinating Primary Care, Hospital Care, laboratories, and health areas to enhance equity, particularly for patients with rare and undiagnosed diseases.
Pablo Prieto highlights that in pediatrics, the creation of DiERCyL has structured care with clinical pathways, ensuring access to genetic tests and specialists from any hospital. “Primary care is key as the entry point to detect initial signs and activate diagnostic routes.”
Pediatric-to-Adult Transition
Most rare diseases have a genetic origin, with symptoms appearing in childhood. Pablo stresses the significance of family ties and the need for a structured and coordinated transition, with support from a case management nurse, to reduce anxiety and ensure continuity in adult medicine.
Early Diagnosis and Networked Care
María Isidoro notes that patients without a diagnosis require special attention to reduce response times. Castilla y León has reduced the average diagnostic age to about five years, especially thanks to DiERCyL’s molecular genetics laboratory.
Pablo details the network model, with three levels of care based on complexity, allowing accurate diagnosis and follow-up without unnecessary travel, improving quality and equity.
Comprehensive Care and Psychosocial Support
María Isidoro comments that the plan includes a comprehensive vision, involving four regional ministries, to address educational, social, and labor aspects. This has been nationally recognized.
Pablo points out that receiving a diagnosis can be either a relief or a shock, and psychological care is activated from the moment of diagnosis, with essential support from patient associations and coordinated work with psychologists and social workers.
Specialized Training
Pablo indicates that in pediatrics, it is essential to have specialists trained in key areas and to reinforce training in clinical genetics to ensure adequate lifelong follow-up. In adults, María Isidoro notes that multidisciplinary clinical coordination and the role of the case manager are essential, as is genetic counseling.
Impact of the Plan
María Luisa Pérez explains that the implementation of the PIERCyL has centralized and optimized the care of adult patients with rare diseases, structuring the organization around five nodes and a pediatric reference unit. She highlights the creation of specific consultations, personnel training, and interdisciplinary collaboration.
This structure has allowed for the early identification of nearly 200 different diseases and has facilitated access to agile diagnosis, orphan treatments, and personalized follow-up, always patient-centered. Psychosocial assessment and connection with associations have been promoted.
Castilla y León: Leading Europe in Personalized Medicine
With the PEMPPCyL and its integrated plans such as the PIERCyL and DIERCyL, Castilla y León is establishing itself as a leader in precision personalized medicine, blending technological innovation, advanced research, healthcare coordination, and an ethical and human-centered approach. The community’s strategic commitment, backed by the regional government and funded with national and European resources, has promoted a more efficient, equitable, and sustainable healthcare model.
The testimonies of María Isidoro, Fermín Sánchez-Guijo, Pablo Prieto, and María Luisa Pérez highlight the dedication and rigor with which Castilla y León is developing a system capable of offering individualized treatments and diagnoses, reducing response times, improving the quality of life for patients with rare diseases, and advancing towards a future where medicine truly adapts to each individual.
This plan not only enhances healthcare but also boosts biosanitary competitiveness, research, and regional innovation, aligning with the best European practices and contributing to the social and economic well-being of Castilla y León.
Frequently Asked Questions
What is the PEMPPCyL?
The Strategic Plan for Precision Personalized Medicine in Castilla y León, a comprehensive initiative aiming to transform the regional healthcare system by using advanced technologies like genomics and AI to provide more personalized and effective care.
What are RANs and RMTs?
RANs (Reference Assistance Nodes) are advanced laboratories, and RMTs (Reference Multidisciplinary Teams) are specialized healthcare teams. They work together to deliver precision medicine and personalized care.
What role does the PIERCyL play?
The PIERCyL (Integral Plan for Rare Diseases of Castilla y León) is a key part of the PEMPPCyL, focusing on improving care and access to treatments for patients with rare diseases.
How does Castilla y León plan to improve healthcare equity?
The plan promotes equity by coordinating care through a network of hospitals, primary care, and specialized units, ensuring that all residents, regardless of location, have access to advanced medical care.
Want to learn more about the future of healthcare and the impact of precision medicine? Explore our related articles and subscribe to our newsletter for the latest updates!
